Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > News > Natco Pharma launches Albupax for breast cancer treatment

September 19th, 2008

Natco Pharma launches Albupax for breast cancer treatment

Abstract:
Natco Pharma, the Hyderabad-based pharma company has launched Albupax, a nanotechnology drug for treatment of breast cancer.



Also Read

News Now

Paper

Specials
- Bulls Day Out: Sensex gains 727pts on global cues
- FIIs net buy Rs 1,016cr, DIIs net buy Rs 44cr
- PM holds second CCEA meeting to review the global financial situation
- Global markets rally; Hang Seng, Shanghai soar 9%
- ONGC to invest Rs 19,338 cr in oil & gas exploration
- PM to chair meeting on Integrated Energy Policy
More

Also Read

News Now

Paper

Specials

- Sensex rallies on FM-speak, global cues
- Tata Motors holds talks with Karnataka for alternative Nano site
- Government opens a new page for foreign news magazines
- Nasscom's $60 bn export target in jeopardy
- Ranbaxy appoints Giuliani firm to counter FDA ruling
More

Also Read

News Now

Paper

Specials

- Subprime Crisis: US faces economic turmoil
- Fighting Inflation : Inflation at a 13-year high
- Your Money : Personal finance
- Credit Policy : RBI's monetary policy review
- Tracking the downturn : Economic slowdown and its impact
- Time Out : food, travel, sports, health...
More

Over a lakh new incidences of breast cancer are reported in India every year.

Albupax has been indigenously developed by Natco in India. The company has priced each 100 milligram (mg) vial of the drug at Rs 11,500. The estimated domestic market for this product is around Rs 150 crore.

Source:
business-standard.com

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Nanomedicine

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

JPK reports on the use of a NanoWizard AFM system at the University of Kaiserslautern to study the interaction of bacteria with microstructured surfaces April 28th, 2016

Announcements

Personal cooling units on the horizon April 29th, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic